Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed dose comparison in previously treated advanced NSCLC
NCT00191191Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2004
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Best Overall Response up to 3.2 years. Started Oct 2004; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00191191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191191.